Best TRT and Men’s Health Telehealth Platforms

Which platforms belong on the initial shortlist?

Vendor descriptions below reflect official pages reviewed as of October 22, 2026. These are candidates for a scoped evaluation, not a claim that every listed vendor offers every treatment or state. The right-hand column is our procurement analysis.

What makes TRT platform selection different from a general telehealth purchase?

TRT procurement starts with a clinical pathway, not a list of testosterone products. Your operating plan must distinguish the commercial brand, the medical entity, individual clinicians, laboratories and dispensing pharmacies. A business dashboard can coordinate those parties, but it should not collapse their responsibilities into a single “approve order” button controlled by the brand owner.

Write a one-page service specification before requesting demos. Identify the patient group the independent clinical team is prepared to assess, the states in the initial rollout, the types of appointments, the lab workflow and how people are referred elsewhere when the program is unsuitable. Ask the clinical team to define the medical criteria. Your job as the operator is to make the required steps visible and reliably executable.

A vendor advertising men’s health may mean ED, hair loss, general consultations or other programs. That category label is not evidence of a current TRT offering. Similarly, the ability to send a prescription electronically is not enough to establish that a particular clinician may prescribe a particular controlled medication through your proposed remote workflow. Our TRT brand launch guide helps organize the operating questions without substituting for clinical protocols.

How should you test visits, labs and renewals in a demo?

Ask every finalist to run the same synthetic patient journey. Begin with a new patient who completes an intake but has not supplied the required records. Watch how the system identifies the missing step, routes the case and communicates the next action. Then add a lab result and ask who receives it, who reviews it, and where the review and follow-up are recorded. A polished portal matters less than a clear work queue when a result needs attention.

Next test a returning patient whose renewal requires another clinical action. The payment subscription and the medical decision should be separate states. Ask what happens if a commercial renewal date arrives before the clinician is ready to authorize treatment. Can support explain the status without making a medical recommendation? Can billing be paused or corrected according to the agreed policy? Can the patient see a useful next step instead of a generic failed-order message?

Finally, demonstrate an exception: an unavailable provider, an unreturned lab result, a pharmacy rejection or a patient who has moved. Require a named operational owner for each queue and an escalation route for clinical questions. Use fictional records for procurement testing. The goal is to see whether the workflow handles incomplete information, not to simulate a treatment decision.

Which prescribing rules need a current review?

For controlled-medication workflows, review the actual federal and state requirements with the responsible clinical organization. The DEA’s 2026 extension announcement describes temporary telemedicine flexibilities through December 31, 2026. It does not make every asynchronous questionnaire sufficient for controlled prescribing, and it does not remove other applicable requirements.

The practical procurement question is how the vendor keeps the program current when a rule changes. Ask who monitors policy, who approves protocol changes, how affected patients are identified, and whether new visit requirements can be introduced without breaking the subscription or record history. Put a review date and accountable clinical owner in the implementation plan.

Treat a vague “compliant nationwide” answer as the start of the conversation, not the completed service specification. You need the states, clinicians, visit modes, medication scope and exceptions for your program. The Ryan Haight and asynchronous prescribing guide explains why platform capability and prescribing authority are separate questions.

How do you compare TRT economics without hiding service costs?

Build the cost model around completed care journeys rather than prescription revenue alone. Request the platform subscription, implementation fee, clinical visit charges, lab costs, pharmacy charges, shipping, payment processing, support and any renewal or cancellation charges. Separate a fee incurred when a consultation happens from a fee incurred only after a fulfillment event. Do not assume the same billing trigger across vendors.

Use three operational scenarios: a new evaluation that proceeds through the agreed pathway, an evaluation that does not lead to prescribing, and a returning patient who needs additional follow-up. The clinician’s decision must remain independent of whether the brand considers a case commercially attractive. Your financial model should absorb the legitimate cost of an assessment that does not create a medication sale.

TEHR uses a flat platform subscription and flat transaction fee with 0% revenue share. That commercial structure does not mean clinical care, medication, labs or optional support are free. Review the TEHR pricing scope and use the TEHR pricing calculator to test explicit assumptions. Compare the same service specification in every proposal; a cheap software seat is not the same purchase as a staffed clinical program.

What should an existing TRT brand require from migration?

An existing patient count is only one input to migration planning. Inventory the records that explain the current treatment relationship: encounter history, prior lab results, current medication information, consent records, upcoming appointments, renewal schedules and unresolved messages. Ask which information can be imported as structured fields and which will be available as attached records. Agree how clinicians will access both.

Do not treat an imported prescription history as an automatic new authorization. The receiving clinical team decides what review is necessary. Organize cohorts around operational readiness and upcoming care events rather than moving every record because a file upload succeeded. Patients approaching a renewal or a scheduled assessment may need a different communication path from inactive accounts.

Use the migration checklist to assign export, mapping, validation and cutover owners. Rehearse a small cohort and reconcile it before expanding. A useful acceptance report shows what transferred, what failed, what requires clinical attention and which team is responsible for the remaining work. Preserve access to records that must be retained even after the new platform is live.

When should you choose TEHR or another operating model?

Choose TEHR when you want the brand, patient experience and administrative workflows coordinated around independent clinical care, and you prefer a flat subscription and transaction model. Bring the actual TRT requirements to the demo so the team can establish supported scope rather than inferring it from the broader platform.

A clinical-infrastructure vendor may fit better if your team already operates a mature storefront, billing system and support organization and primarily needs clinical capacity or an integration. A broader platform may fit if it can replace more of your current stack without losing the workflows your clinical team depends on. Do not rank these choices by the number of product-menu items alone.

Before selecting a vendor, require a written launch scope, a demonstrated exception workflow, an itemized proposal and a migration or implementation acceptance plan. Compare the same evidence in our platform comparisons. The strongest choice is the one your team can operate consistently after launch, including the days when a patient cannot proceed as expected.

Bring the people who will own the service into the final review: a brand operator, the clinical lead, the implementation owner and the person responsible for patient support. Ask each to identify the unresolved handoffs in the demonstrated workflow. Record those items in the launch scope with an accountable owner, rather than leaving them as informal sales-call promises.

What else should you know?